AstraZeneca PLC
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AZN.L | PFE | MRK | NVS | BMY | BIIB | |
|---|---|---|---|---|---|---|
| Market cap | 193.03B | 168.60B | 360.08B | 286.29B | 122.05B | 34.37B |
| P/E (TTM) | 24.1 | 38.9 | 115.8 | 22.8 | 13.2 | 41.3 |
| Forward P/E | 14.5 | 10.2 | 15.7 | 15.4 | 9.0 | 14.1 |
| Price/book | 5.1 | 2.0 | 8.6 | 6.9 | 5.5 | 1.8 |
| Dividend yield | 1.94% | 5.81% | 2.33% | 3.15% | 4.22% | — |
| 1-year change | +1.11% | +19.81% | +69.08% | +14.29% | +37.07% | +58.66% |
| Today | −1.98% | +0.48% | +0.52% | +0.16% | −1.35% | −1.15% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All AZN.L news ›AstraZeneca, Insitro strike AI drug discovery deal
Fox Business AstraZeneca, Insitro strike AI drug discovery deal Baird investment strategist Ross Mayfield discusses the impact of artificial intelligence on the healthcare industry on ‘The Claman Countdown.’
AstraZeneca collaborates to identify novel drug targets
AstraZeneca has entered a partnership with AI therapeutics company insitro. Using advanced AI systems, the collaboration will identify novel drug targets and advance the design of new therapeutics for patients with metabolic…
AstraZeneca inks AI drug discovery deal worth up to $1.5B with insitro
Seeking Alpha Robert Way/iStock Editorial via Getty Images AstraZeneca (AZN) on Thursday announced an AI-driven drug discovery and licensing deal worth up to $1.5B with California-based insitro, the Anglo-Swedish drugmaker’s latest…
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
Large pharmaceutical companies including Gilead Sciences, Roche and AstraZeneca spent this week securing access to discovery technologies and experimental candidates that address clear biological gaps, instead of large-scale acquisitions…
AstraZeneca Stock Analysis: Gains 3.24%, Testing Key Resistance
JournalArta AstraZeneca Stock Analysis: Gains 3.24%, Testing Key Resistance On October 15, 2026: price 12,698.00 GBp, trend sideways, RSI 61.3, support 11,764.00, resistance 12,698.00. technical analysis of astrazeneca stock. Why…
While the market panics about the FTSE 100, Citi just raised its AstraZeneca target to £186
With all the doom and gloom surrounding the FTSE 100, it’s promising to see a major broker up its target for one of the index’s largest listings. When a FTSE 100 giant falls 12% in a year, investors start asking whether the smart money…
AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership
This deal with insitro sees AstraZeneca double down on its intention to enter the growing MASH market. AstraZeneca has inked a billion-dollar artificial intelligence (AI)-powered drug discovery partnership and licensing deal with insitro,…
AstraZeneca taps 'Virtual Human' AI in $1.5 billion deal to develop liver, heart disease drugs
AstraZeneca has teamed up with artificial intelligence biotech company insitro to discover and develop new treatments for difficult to treat liver and heart conditions, the British drugmaker said on Thursday. Under the agreement,…
Health: AstraZeneca strikes $40 million AI drug discovery deal with insitro
Mon, 05 Oct 2026 Fri, 16 Oct 2026 Sat, 10 Oct 2026 Fri, 09 Oct 2026 Mon, 12 Oct 2026 Tue, 06 Oct 2026 Wed, 14 Oct 2026 Tue, 13 Oct 2026 Thu, 15 Oct 2026 Thu, 08 Oct 2026 LONDON: AstraZeneca has teamed up with artificial intelligence…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com33
-
tradingview.com16
-
themarketsdaily.com7
-
biospace.com6
-
openpr.com5
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.